Metabolic reprogramming of drug resistance in pancreatic cancer: mechanisms and effects
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Pancreatic cancer
Area Of Science
- Gastrointestinal Oncology
- Cancer Metabolism
- Epigenetics
Background
- Pancreatic cancer is a deadly malignancy with high mortality.
- Late diagnosis and chemoresistance complicate treatment.
- Metabolic reprogramming is crucial for cancer cell growth.
Purpose Of The Study
- To review the link between metabolic reprogramming and chemotherapy resistance in pancreatic cancer.
- To discuss the mechanisms driving these processes.
- To summarize therapeutic strategies targeting cancer metabolism.
Main Methods
- Literature review of preclinical studies.
- Analysis of mechanisms of metabolic reprogramming.
- Summary of drug development targeting metabolic pathways.
Main Results
- Metabolic alterations support pancreatic cancer proliferation and metastasis.
- Epigenetic mechanisms may mediate metabolic changes.
- Targeting metabolism shows promise in preclinical models.
Conclusions
- Metabolic reprogramming is a key driver of pancreatic cancer and chemoresistance.
- Targeting metabolic pathways offers potential therapeutic strategies.
- Further research is needed to translate these findings into clinical practice.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...